Cargando…

Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats

BACKGROUND: The intestinal epithelium is a barrier that composes one of the most immunologically active surfaces of the body due to constant exposure to microorganisms as well as an infinite diversity of food antigens. Disruption of intestinal barrier function and aberrant mucosal immune activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Valladares, Ricardo, Sankar, Dhyana, Li, Nan, Williams, Emily, Lai, Kin-Kwan, Abdelgeliel, Asmaa Sayed, Gonzalez, Claudio F., Wasserfall, Clive H., Larkin, Joseph, Schatz, Desmond, Atkinson, Mark A., Triplett, Eric W., Neu, Josef, Lorca, Graciela L.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865539/
https://www.ncbi.nlm.nih.gov/pubmed/20463897
http://dx.doi.org/10.1371/journal.pone.0010507
_version_ 1782180854201581568
author Valladares, Ricardo
Sankar, Dhyana
Li, Nan
Williams, Emily
Lai, Kin-Kwan
Abdelgeliel, Asmaa Sayed
Gonzalez, Claudio F.
Wasserfall, Clive H.
Larkin, Joseph
Schatz, Desmond
Atkinson, Mark A.
Triplett, Eric W.
Neu, Josef
Lorca, Graciela L.
author_facet Valladares, Ricardo
Sankar, Dhyana
Li, Nan
Williams, Emily
Lai, Kin-Kwan
Abdelgeliel, Asmaa Sayed
Gonzalez, Claudio F.
Wasserfall, Clive H.
Larkin, Joseph
Schatz, Desmond
Atkinson, Mark A.
Triplett, Eric W.
Neu, Josef
Lorca, Graciela L.
author_sort Valladares, Ricardo
collection PubMed
description BACKGROUND: The intestinal epithelium is a barrier that composes one of the most immunologically active surfaces of the body due to constant exposure to microorganisms as well as an infinite diversity of food antigens. Disruption of intestinal barrier function and aberrant mucosal immune activation have been implicated in a variety of diseases within and outside of the gastrointestinal tract. With this model in mind, recent studies have shown a link between diet, composition of intestinal microbiota, and type 1 diabetes pathogenesis. In the BioBreeding rat model of type 1 diabetes, comparison of the intestinal microbial composition of diabetes prone and diabetes resistant animals found Lactobacillus species were negatively correlated with type 1 diabetes development. Two species, Lactobacillus johnsonii and L. reuteri, were isolated from diabetes resistant rats. In this study diabetes prone rats were administered pure cultures of L. johnsonii or L. reuteri isolated from diabetes resistant rats to determine the effect on type 1 diabetes development. METHODOLOGY/PRINCIPAL: Findings Results Rats administered L. johnsonii, but not L. reuteri, post-weaning developed type 1 diabetes at a protracted rate. Analysis of the intestinal ileum showed administration of L. johnsonii induced changes in the native microbiota, host mucosal proteins, and host oxidative stress response. A decreased oxidative intestinal environment was evidenced by decreased expression of several oxidative response proteins in the intestinal mucosa (Gpx1, GR, Cat). In L. johnsonii fed animals low levels of the pro-inflammatory cytokine IFNγ were correlated with low levels of iNOS and high levels of Cox2. The administration of L. johnsonii also resulted in higher levels of the tight junction protein claudin. CONCLUSIONS: It was determined that the administration of L. johnsonii isolated from BioBreeding diabetes resistant rats delays or inhibits the onset of type 1 diabetes in BioBreeding diabetes prone rats. Taken collectively, these data suggest that the gut and the gut microbiota are potential agents of influence in type 1 diabetes development. These data also support therapeutic efforts that seek to modify gut microbiota as a means to modulate development of this disorder.
format Text
id pubmed-2865539
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28655392010-05-12 Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats Valladares, Ricardo Sankar, Dhyana Li, Nan Williams, Emily Lai, Kin-Kwan Abdelgeliel, Asmaa Sayed Gonzalez, Claudio F. Wasserfall, Clive H. Larkin, Joseph Schatz, Desmond Atkinson, Mark A. Triplett, Eric W. Neu, Josef Lorca, Graciela L. PLoS One Research Article BACKGROUND: The intestinal epithelium is a barrier that composes one of the most immunologically active surfaces of the body due to constant exposure to microorganisms as well as an infinite diversity of food antigens. Disruption of intestinal barrier function and aberrant mucosal immune activation have been implicated in a variety of diseases within and outside of the gastrointestinal tract. With this model in mind, recent studies have shown a link between diet, composition of intestinal microbiota, and type 1 diabetes pathogenesis. In the BioBreeding rat model of type 1 diabetes, comparison of the intestinal microbial composition of diabetes prone and diabetes resistant animals found Lactobacillus species were negatively correlated with type 1 diabetes development. Two species, Lactobacillus johnsonii and L. reuteri, were isolated from diabetes resistant rats. In this study diabetes prone rats were administered pure cultures of L. johnsonii or L. reuteri isolated from diabetes resistant rats to determine the effect on type 1 diabetes development. METHODOLOGY/PRINCIPAL: Findings Results Rats administered L. johnsonii, but not L. reuteri, post-weaning developed type 1 diabetes at a protracted rate. Analysis of the intestinal ileum showed administration of L. johnsonii induced changes in the native microbiota, host mucosal proteins, and host oxidative stress response. A decreased oxidative intestinal environment was evidenced by decreased expression of several oxidative response proteins in the intestinal mucosa (Gpx1, GR, Cat). In L. johnsonii fed animals low levels of the pro-inflammatory cytokine IFNγ were correlated with low levels of iNOS and high levels of Cox2. The administration of L. johnsonii also resulted in higher levels of the tight junction protein claudin. CONCLUSIONS: It was determined that the administration of L. johnsonii isolated from BioBreeding diabetes resistant rats delays or inhibits the onset of type 1 diabetes in BioBreeding diabetes prone rats. Taken collectively, these data suggest that the gut and the gut microbiota are potential agents of influence in type 1 diabetes development. These data also support therapeutic efforts that seek to modify gut microbiota as a means to modulate development of this disorder. Public Library of Science 2010-05-06 /pmc/articles/PMC2865539/ /pubmed/20463897 http://dx.doi.org/10.1371/journal.pone.0010507 Text en Valladares et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Valladares, Ricardo
Sankar, Dhyana
Li, Nan
Williams, Emily
Lai, Kin-Kwan
Abdelgeliel, Asmaa Sayed
Gonzalez, Claudio F.
Wasserfall, Clive H.
Larkin, Joseph
Schatz, Desmond
Atkinson, Mark A.
Triplett, Eric W.
Neu, Josef
Lorca, Graciela L.
Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title_full Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title_fullStr Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title_full_unstemmed Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title_short Lactobacillus johnsonii N6.2 Mitigates the Development of Type 1 Diabetes in BB-DP Rats
title_sort lactobacillus johnsonii n6.2 mitigates the development of type 1 diabetes in bb-dp rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865539/
https://www.ncbi.nlm.nih.gov/pubmed/20463897
http://dx.doi.org/10.1371/journal.pone.0010507
work_keys_str_mv AT valladaresricardo lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT sankardhyana lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT linan lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT williamsemily lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT laikinkwan lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT abdelgelielasmaasayed lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT gonzalezclaudiof lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT wasserfallcliveh lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT larkinjoseph lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT schatzdesmond lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT atkinsonmarka lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT triplettericw lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT neujosef lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats
AT lorcagracielal lactobacillusjohnsoniin62mitigatesthedevelopmentoftype1diabetesinbbdprats